SYNTHESIS, LSD1 INHIBITORY ACTIVITY, AND LSD1 BINDING MODEL OF OPTICALLY PURE LYSINE-PCPA CONJUGATES
Compounds that inhibit the catalytic function of lysine-specific demethylase 1 (LSD1) are interesting as therapeutic agents. Recently, we identified three lysine-phenylcyclopropylamine conjugates, NCD18, NCD25, and NCD41, which are potent LSD1 inactivators. However, in our previous study, because we...
Main Authors: | Yukihiro Itoh, Daisuke Ogasawara, Yosuke Ota, Tamio Mizukami, Takayoshi Suzuki |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-02-01
|
Series: | Computational and Structural Biotechnology Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037014600052 |
Similar Items
-
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
by: Zizhen Feng, et al.
Published: (2016-03-01) -
Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles
by: Lea M. Stitzlein, et al.
Published: (2023-04-01) -
Knocking down LSD1 inhibits the stemness features of colorectal cancer stem cells
by: J. Chen, et al. -
Natural products as LSD1 inhibitors for cancer therapy
by: Yuan Fang, et al.
Published: (2021-03-01) -
Expanding the Role of the Histone Lysine-Specific Demethylase LSD1 in Cancer
by: Barbara Majello, et al.
Published: (2019-03-01)